◆英語タイトル:Pharnext SA (ALPHA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8035
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Pharnext SA (Pharnext), formerly Pharnext SAS is a biopharmaceutical company that develops novel therapies for severe neurodegenerative diseases. The company offers pleotherapy, a proprietary research and development platform based on network pharmacology that uses wide genomic data to identify molecules related to specific diseases and facilitates the development of synergistic combinations of drugs. Its develops lead pleodrugs, which include PXT-3003, for Charcot-Marie-Tooth disease type 1A; and PXT-864, for Alzheimer’s disease and other neurological indications including Parkinson’s disease and amyotrophic lateral sclerosis. The company’s pleodrug are tested in humans through a complete clinical development plan. Pharnext is headquartered in Paris, France.
Pharnext SA (ALPHA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharnext SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Pharnext SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharnext SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Pharnext Raises Additional US$11.2 Million In Venture Financing 10
Partnerships 11
Pharnext to Form Joint Venture with Tasly Pharma 11
Pharnext Enters into Research Agreement with Galapagos 12
Pharnext Partners with OrphanDev 13
Licensing Agreements 14
Pharnext to Enter into Licensing Agreement with Tasly Pharma 14
Equity Offering 15
Pharnext Raises USD7.5 Million in Private Placement of Shares and Warrants 15
Pharnext to Raise USD5.5 Million in Private Placement of Shares 16
Pharnext Raises USD34.4 Million in IPO of Shares 17
Debt Offering 18
Pharnext Raises USD12.3 Million in Private Placement of 6.9% Bonds 18
Pharnext to Raise USD16.4 Million in Private Placement of 5% Bonds 19
Pharnext SA – Key Competitors 20
Pharnext SA – Key Employees 21
Pharnext SA – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Apr 12, 2018: Pharnext Reports Financial Results for Year-End 2017 23
Oct 19, 2017: Pharnext: First-Half 2017 25
Apr 26, 2017: Pharnext Reports Year End 2016 Financial Results 27
Corporate Communications 29
Sep 17, 2018: Pharnext names David Stout as Board Director 29
Jan 02, 2018: Dr. Philippe Chambon Joins Pharnext’s Board of Directors 30
Product News 31
07/10/2017: Pharnext to Present PXT864 Data at the Alzheimer’s Association International Conference 2017 31
Feb 02, 2017: Pharnext Announces Findings Evaluating Charcot-Marie-Tooth Neuropathy Score 32
Clinical Trials 33
Mar 29, 2017: Pharnext to Present New PXT864 Synergy Data at AD/PD 2017, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders 33
Other Significant Developments 34
Oct 09, 2018: Vitaccess and Pharnext launch international CMT&Me observational study 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Tables
Pharnext SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharnext SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharnext SA, Deals By Therapy Area, 2012 to YTD 2018 8
Pharnext SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharnext Raises Additional US$11.2 Million In Venture Financing 10
Pharnext to Form Joint Venture with Tasly Pharma 11
Pharnext Enters into Research Agreement with Galapagos 12
Pharnext Partners with OrphanDev 13
Pharnext to Enter into Licensing Agreement with Tasly Pharma 14
Pharnext Raises USD7.5 Million in Private Placement of Shares and Warrants 15
Pharnext to Raise USD5.5 Million in Private Placement of Shares 16
Pharnext Raises USD34.4 Million in IPO of Shares 17
Pharnext Raises USD12.3 Million in Private Placement of 6.9% Bonds 18
Pharnext to Raise USD16.4 Million in Private Placement of 5% Bonds 19
Pharnext SA, Key Competitors 20
Pharnext SA, Key Employees 21
List of Figures
Pharnext SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharnext SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharnext SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8